2019
DOI: 10.1002/slct.201901728
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro Investigation of Controlled Release of Ciprofloxacin and Its β‐Cyclodextrin Inclusion Complex from Gelatin Grafted Poly(vinyl alcohol) (GPVA) Nanoparticles

Abstract: Controlled drug delivery is one of the probable answers to different problems associated with conventional dosing regimens. Ciprofloxacin (CFX) is an antibiotic, signifying second generation fluoroquinolone which is active against wide‐ranges of microbes. Due to low solubility and bioavailability, it requires a controlled release device for its delivery. An attempt has been made in the present work to develop gelatin grafted poly (vinyl alcohol) (GPVA) hydrogel nanoparticle and study the release behaviour of C… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…It works by targeting bacterial DNA gyrase and is commonly used for treating skin infections and ocular infections [16][17][18] . One of the limitations of the drug is the low half-life (approximately 4 h); therefore sustained or prolonged effect of the drug could not be achieved by conventional therapy [19][20][21] . A recent study involved loading of CIP into PLGA microspheres in combination with inhibitor ginsenoside Rh2 for treating S. aureus infections showed sustained release of the drug and was validated through in vivo studies 22 .…”
Section: Introductionmentioning
confidence: 99%
“…It works by targeting bacterial DNA gyrase and is commonly used for treating skin infections and ocular infections [16][17][18] . One of the limitations of the drug is the low half-life (approximately 4 h); therefore sustained or prolonged effect of the drug could not be achieved by conventional therapy [19][20][21] . A recent study involved loading of CIP into PLGA microspheres in combination with inhibitor ginsenoside Rh2 for treating S. aureus infections showed sustained release of the drug and was validated through in vivo studies 22 .…”
Section: Introductionmentioning
confidence: 99%